Literature DB >> 25932218

Systemic side effects of locally used oxymetazoline.

Recep Dokuyucu1, Hasan Gokce2, Mustafa Sahan3, Fatih Sefil1, Zeynel Abidin Tas2, Okan Tutuk1, Atakan Ozturk1, Cemil Tumer1, Cengiz Cevik4.   

Abstract

OBJECTIVES: The object of the study is to experimentally investigate the possible systemic side effects of Oxymetazoline including its nasal spray which has been in use for a long time both by the physicians and patients. There is no study in the literature to address the damages of oxymetazoline on the end organ.
MATERIALS AND METHODS: The study conducted on 2 groups of rat. Group 1 (n = 8): Control; and Group 2 (n = 8): Oxymetazoline. During 4 week, the control group was applied with 2 drops of saline water on each nasal cavity 3 times a day and the other group was applied with 2 drops of oxymetazoline HCl 3 times a day. At the end of experiment, samples from mandible, parotid and tails of the rats were taken in 10% formalin for histopathological investigations.
RESULTS: In histopathological experiments, when compared with the control group, the oxymetazoline group showed significant increase in many of the histopathological parameters (ischemic changes: P = 0.0001; congestion: P = 0.0006; arterial thrombosis: P = Ns; PNL accumulations: P = 0.001; necrosis: P = 0.0001; and ulceration: P = 0.014). The results of histopathologic tests on the samples taken from mandible and parotid gland, in comparison with the control group, showed no significant increase (focal inflammation: P = Ns; and lymphocyte aggregation: P = Ns).
CONCLUSION: Due to the damage that the long-term use of nasal spray including oxymetazoline, it may cause injury on the end organ, which we revealed in our histopathological experiments. We believe that it's essential for the physicians to provide information on the side effects of the medicine to their patients who use for a long term.

Entities:  

Keywords:  Nasal spray; end-organ injury; oxymetazoline; systemic side effects

Year:  2015        PMID: 25932218      PMCID: PMC4402865     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  13 in total

1.  Are nasal decongestants safer than rhinitis? A case of oxymetazoline-induced syncope.

Authors:  Marianna Fabi; Roberto Formigari; Fernando M Picchio
Journal:  Cardiol Young       Date:  2009-09-23       Impact factor: 1.093

2.  CNS reactions to nose drops in small children.

Authors:  P Söderman; D Sahlberg; B E Wiholm
Journal:  Lancet       Date:  1984-03-10       Impact factor: 79.321

3.  Paranoid psychosis induced by oxymetazoline nasal spray.

Authors:  B Ticoll; G Shugar
Journal:  CMAJ       Date:  1994-02-01       Impact factor: 8.262

Review 4.  Rhinitis medicamentosa.

Authors:  J T Ramey; E Bailen; R F Lockey
Journal:  J Investig Allergol Clin Immunol       Date:  2006       Impact factor: 4.333

5.  The local vasoconstriction of infant's skin following instillation of mydriatic eye drops.

Authors:  Atilla Alpay; Bahri Ermis; Silay C Ugurbas; Fatih Battal; Haci Murat Sagdik
Journal:  Eur J Clin Pharmacol       Date:  2010-09-11       Impact factor: 2.953

6.  Cerebral vasoconstriction triggered by sympathomimetic drugs during intra-atrerial chemotherapy.

Authors:  Todd Abruzzo; Mario Patino; James Leach; Ralph Rahme; James Geller
Journal:  Pediatr Neurol       Date:  2013-02       Impact factor: 3.372

7.  Oxymetazoline nasal spray three times daily for four weeks in normal subjects is not associated with rebound congestion or tachyphylaxis.

Authors:  H Watanabe; T H Foo; B Djazaeri; P Duncombe; I S Mackay; S R Durham
Journal:  Rhinology       Date:  2003-09       Impact factor: 3.681

8.  Bradycardia, hypotension, and near-syncope associated with Afrin (oxymetazoline) nasal spray.

Authors:  F Glazener; K Blake; M Gradman
Journal:  N Engl J Med       Date:  1983-09-22       Impact factor: 91.245

9.  Cardiac arrest after oxymetazoline nasal spray.

Authors:  D N Thrush
Journal:  J Clin Anesth       Date:  1995-09       Impact factor: 9.452

10.  Determination of oxidative stress and effect of erdosteine on rhinitis medicamentosa in a rat model.

Authors:  Recep Dokuyucu; Cengiz Cevik; Gul Soylu Ozler; Tumay Ozgur; Cengiz Arli; Fatih Sefil; Zafer Yonden
Journal:  Eur J Pharmacol       Date:  2014-09-18       Impact factor: 4.432

View more
  6 in total

Review 1.  Nasoseptal Perforation: from Etiology to Treatment.

Authors:  Carla Pereira; Alfonso Santamaría; Cristobal Langdon; Mauricio López-Chacón; José Hernández-Rodríguez; Isam Alobid
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-05       Impact factor: 4.806

2.  Bioactive components of different nasal spray solutions may defeat SARS-Cov2: repurposing and in silico studies.

Authors:  Mohammad Faheem Khan; Waseem Ahmad Ansari; Tanveer Ahamad; Mohsin Ali Khan; Zaw Ali Khan; Aqib Sarfraz; Mohd Aamish Khan
Journal:  J Mol Model       Date:  2022-07-06       Impact factor: 2.172

Review 3.  Sympathomimetic amine compounds and hepatotoxicity: Not all are alike-Key distinctions noted in a short review.

Authors:  Cyril Willson
Journal:  Toxicol Rep       Date:  2018-12-01

Review 4.  Intranasal drug delivery: opportunities and toxicologic challenges during drug development.

Authors:  Lea-Adriana Keller; Olivia Merkel; Andreas Popp
Journal:  Drug Deliv Transl Res       Date:  2021-01-25       Impact factor: 4.617

Review 5.  Advances and Challenges in Intranasal Delivery of Antipsychotic Agents Targeting the Central Nervous System.

Authors:  Manisha Pandey; Neha Jain; Jovita Kanoujia; Zahid Hussain; Bapi Gorain
Journal:  Front Pharmacol       Date:  2022-03-24       Impact factor: 5.810

6.  Ischemic Stroke Associated with Chronic Xylometazoline Nasal Spray Misuse: A Rare Avoidable Adverse Event.

Authors:  Jalpan Patel; Ishani Patel; Devangi Desai; Soaham Desai
Journal:  Ann Indian Acad Neurol       Date:  2020-07-08       Impact factor: 1.383

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.